Jay Olson
Stock Analyst at Oppenheimer
(4.11)
# 449
Out of 5,245 analysts
249
Total ratings
44.22%
Success rate
15.69%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Perform | $84 → $90 | $97.16 | -7.37% | 15 | Apr 29, 2026 | |
| PASG Passage Bio | Maintains: Outperform | $30 → $15 | $5.23 | +187.08% | 2 | Apr 21, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $150 → $165 | $151.56 | +8.87% | 11 | Apr 13, 2026 | |
| BIIB Biogen | Maintains: Outperform | $250 → $275 | $193.76 | +41.93% | 27 | Apr 1, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $44 → $36 | $4.55 | +691.21% | 5 | Mar 18, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $540 → $600 | $434.52 | +38.08% | 2 | Mar 10, 2026 | |
| BIOA BioAge Labs | Initiates: Outperform | $60 | $16.61 | +261.23% | 1 | Feb 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $21.10 | +9.00% | 16 | Feb 6, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $1.61 | +521.12% | 1 | Jan 22, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $250 → $750 | $343.56 | +118.30% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $650 | $517.26 | +25.66% | 12 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.84 | +171.74% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $90 | $75.56 | +19.11% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $30 | $5.39 | +456.59% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $4.32 | +224.07% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.83 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $3.57 | +1,720.73% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $0.903 | +7,098.23% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.35 | +862.96% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $66.61 | +35.11% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $18.64 | +125.32% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $50.15 | -34.20% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $12.60 | +217.46% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $5.80 | +244.83% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $7.09 | +323.13% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $30.89 | +346.75% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.78 | +349.44% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $339.30 | +12.00% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $156.70 | +39.76% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.76 | +334.78% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.80 | +373.68% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $25.57 | +291.08% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $50.36 | +88.64% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.8293 | +2,914.59% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.26 | +614.29% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.52 | +32,794.74% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $13.96 | +50.43% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.04 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $16.58 | +406.63% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.12 | - | 3 | Jul 11, 2017 |
Incyte
Apr 29, 2026
Maintains: Perform
Price Target: $84 → $90
Current: $97.16
Upside: -7.37%
Passage Bio
Apr 21, 2026
Maintains: Outperform
Price Target: $30 → $15
Current: $5.23
Upside: +187.08%
Revolution Medicines
Apr 13, 2026
Maintains: Outperform
Price Target: $150 → $165
Current: $151.56
Upside: +8.87%
Biogen
Apr 1, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $193.76
Upside: +41.93%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $44 → $36
Current: $4.55
Upside: +691.21%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Outperform
Price Target: $540 → $600
Current: $434.52
Upside: +38.08%
BioAge Labs
Feb 25, 2026
Initiates: Outperform
Price Target: $60
Current: $16.61
Upside: +261.23%
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $21.10
Upside: +9.00%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $1.61
Upside: +521.12%
Praxis Precision Medicines
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $343.56
Upside: +118.30%
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $517.26
Upside: +25.66%
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $1.84
Upside: +171.74%
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $75.56
Upside: +19.11%
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $5.39
Upside: +456.59%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $4.32
Upside: +224.07%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $9.83
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $3.57
Upside: +1,720.73%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $0.903
Upside: +7,098.23%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.35
Upside: +862.96%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $66.61
Upside: +35.11%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $18.64
Upside: +125.32%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $50.15
Upside: -34.20%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $12.60
Upside: +217.46%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $5.80
Upside: +244.83%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $7.09
Upside: +323.13%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $30.89
Upside: +346.75%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.78
Upside: +349.44%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $339.30
Upside: +12.00%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $156.70
Upside: +39.76%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.76
Upside: +334.78%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.80
Upside: +373.68%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $25.57
Upside: +291.08%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $50.36
Upside: +88.64%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.8293
Upside: +2,914.59%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.26
Upside: +614.29%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.52
Upside: +32,794.74%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $13.96
Upside: +50.43%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.04
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $16.58
Upside: +406.63%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.12
Upside: -